TENX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Tenax Therapeutics, Inc. Class Action Lawsuit

Robbins LLP announces a class action lawsuit against Tenax Therapeutics for allegedly misleading investors about the viability of its drug candidate levosimendan. The company's Phase 3 LEVEL trial failed to meet its primary endpoint, causing the stock to plummet 89.77% on August 10, 2026. Investors have until December 28, 2026 to seek lead plaintiff status.